Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands |
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
| Revenues: |
|
|
|
| GI equipment and supplies |
$ 58,454
|
$ 48,824
|
$ 38,772
|
| GI pathology services |
13,846
|
12,595
|
12,119
|
| Net revenues |
72,300
|
61,419
|
50,891
|
| Cost of revenues: |
|
|
|
| GI equipment and supplies |
43,745
|
33,815
|
21,502
|
| GI pathology services |
5,245
|
5,093
|
4,390
|
| Cost of revenues |
48,990
|
38,908
|
25,892
|
| Gross profit |
23,310
|
22,511
|
24,999
|
| Operating expenses: |
|
|
|
| Research and development |
17,288
|
21,702
|
16,617
|
| Sales and marketing |
30,367
|
27,660
|
18,148
|
| General and administrative |
23,158
|
16,456
|
11,355
|
| Amortization of intangible assets |
2,753
|
3,908
|
4,578
|
| Operating expenses |
73,566
|
69,726
|
50,698
|
| Operating loss |
(50,256)
|
(47,215)
|
(25,699)
|
| Other income (expense): |
|
|
|
| Other income (expense) |
(1,793)
|
(1,563)
|
327
|
| Interest expense |
(5,414)
|
(3,950)
|
(104)
|
| Loss on early retirement of debt |
(2,282)
|
0
|
0
|
| Total other income (expense) |
(9,489)
|
(5,513)
|
223
|
| Net loss before income taxes |
(59,745)
|
(52,728)
|
(25,476)
|
| Income tax benefit (expense) |
361
|
(916)
|
1,558
|
| Net loss |
(59,384)
|
(53,644)
|
(23,918)
|
| Other comprehensive income (loss): |
|
|
|
| Foreign currency translation adjustments |
562
|
(5,064)
|
3,050
|
| Change in fair value of available-for-sale securities |
(116)
|
0
|
0
|
| Other comprehensive loss |
446
|
(5,064)
|
3,050
|
| Comprehensive loss |
$ (58,938)
|
$ (58,708)
|
$ (20,868)
|
| Net loss per share attributable to common stockholders, basic and diluted (in usd per share) |
$ (2.82)
|
$ (4.30)
|
$ (1.99)
|
| Weighted-average shares of common stock used to compute net loss per share attributable to common stockholders, basic and diluted (in shares) |
21,076,246
|
12,482,988
|
12,044,447
|